New hope for kids with Drug-Resistant TB: pretomanid dose study completed

NCT ID NCT05586230

Completed Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a single dose of the drug pretomanid in 32 children with rifampicin-resistant tuberculosis (TB). The goal was to see how the drug moves through the body and whether it is safe when added to their regular TB treatment. The children were monitored for 48 hours after taking the drug. This is an early step toward finding better treatments for children with hard-to-treat TB.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pretomanid
What this could lead to: If successful, this could help determine the right dose of pretomanid for children with drug-resistant TB, potentially leading to better treatment options.
What could go wrong: This is a very early phase 1 study with only 32 children and a single dose. It focuses on safety and drug levels, not on curing the disease. More research is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RIFAMPICIN-RESISTANT TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rifampicin-resistant tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RIFAMPICIN-RESISTANT TUBERCULOSIS TUBERCULOSIS

Contacts and locations

Locations

Site 31441, BJMC CRS

Pune, India
Site 31790, Desmond Tutu TB Centre (DTTC) CRS

Cape Town, South Africa
Site 31929, Sizwe CRS

Johannesburg, South Africa
Site 31976, PHRU Matlosana CRS

Klerksdorp, North West, 2574, South Africa
Site 5071, Instituto de Puericultura e Pediatria Martagao Gesteira CRS

Rio de Janeiro, Brazil
Site 5115, Siriraj Hospital, Mahidol University NICHD CRS

Bangkok Noi, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.